Literature DB >> 3137265

Multiple genomic defects result in an alternative RNA splice creating a human gamma H chain disease protein.

P Guglielmi1, A Bakhshi, M Cogne, M Seligmann, S J Korsmeyer.   

Abstract

Heavy chain diseases (HCD) are human lymphoproliferative disorders in which a clonal B cell population produces Ig molecules made of truncated H chains without associated L chain. We characterized the rearranged H chain gene and its mRNA from the leukemic cells of a patient (RIV) with gamma-HCD. The abnormal RIV serum Ig consisted of shortened, dimeric gamma 1-chains which had an amino terminus within the hinge region. RIV lymphoblasts possessed a foreshortened (1200 bp) gamma 1-mRNA which had sequences for only the leader, hinge, second, and third constant region domains (CH2 + CH3), but lacked variable (VH) and CH1 information. Sequence of the productive gamma 1 allele revealed it had undergone VH-JH and H chain class switch recombinations. However, normal RNA splice sites had been eliminated by a DNA insertion/deletion (VH acceptor site), mutations (JH donor site), or a large deletion (CH1 region). Inserted sequences were of non-Ig and apparently non-genomic origin. These DNA alterations resulted in aberrant mRNA processing in which the leader region was spliced directly to the hinge region, accounting for the HCD protein.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137265

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Spontaneous deletions in Ig heavy chain genes: flanking sequences influence splice site selection.

Authors:  S B Ward; S L Morrison
Journal:  Nucleic Acids Res       Date:  1991-12-11       Impact factor: 16.971

2.  Immunoglobulin heavy-chain-associated amyloidosis.

Authors:  M Eulitz; D T Weiss; A Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

3.  An aberrant splicing using a 3' cryptic splice site within the CH1 exon induces truncated mu-chain production.

Authors:  T Komori; H Sugiyama
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.